Physioneal 40 Glucose 3,86% w/v/38,6 mg/ml šķīdums peritoneālai dialīzei Letland - lettisk - Zāļu valsts aģentūra

physioneal 40 glucose 3,86% w/v/38,6 mg/ml šķīdums peritoneālai dialīzei

baxter latvia, sia, latvia - glikozes monohydricum, kalcija chloridum, magnija chloridum, natrii lactas, natrii chloridum, natrii hydrogenocarbonas - Šķīdums peritoneālai dialīzei - 38,6 mg/ml

Physioneal 40 Glucose 2,27% w/v/22,7 mg/ml šķīdums peritoneālai dialīzei Letland - lettisk - Zāļu valsts aģentūra

physioneal 40 glucose 2,27% w/v/22,7 mg/ml šķīdums peritoneālai dialīzei

baxter latvia, sia, latvia - glikozes monohydricum, kalcija chloridum, magnija chloridum, natrii chloridum, natrii lactas, natrii hydrogenocarbonas - Šķīdums peritoneālai dialīzei - 22,7 mg/ml

Dovato Den Europæiske Union - lettisk - EMA (European Medicines Agency)

dovato

viiv healthcare b.v. - dolutegravir nātrija, lamivudīnu - hiv infekcijas - pretvīrusu līdzekļi sistēmiskai lietošanai - dovato ir indicēts, lai ārstētu cilvēku imūndeficīta vīrusa tips 1 (hiv-1) infekciju pieaugušajiem un pusaudžiem virs 12 gadiem, kas sver vismaz 40 kg, nav zināms vai ir aizdomas par pretestību integrase inhibitoru klases, vai lamivudīnu.

Staquis Den Europæiske Union - lettisk - EMA (European Medicines Agency)

staquis

pfizer europe ma eeig  - crisaborole - dermatīts, atopisks - citi dermatoloģiski preparāti - staquis ir indicēts, lai ārstētu vieglas līdz vidēji atopiskā dermatīta pieaugušajiem un pediatrijas pacientiem no 2 gadu vecuma ar ≤ 40% ķermeņa virsmas (bsa) ietekmēt.

Veklury Den Europæiske Union - lettisk - EMA (European Medicines Agency)

veklury

gilead sciences ireland uc - remdesivir - covid-19 virus infection - veklury is indicated for the treatment of coronavirus disease 2019 (covid 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.

Ronapreve Den Europæiske Union - lettisk - EMA (European Medicines Agency)

ronapreve

roche registration gmbh  - casirivimab, imdevimab - covid-19 virus infection - un imūnglobulīni, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. skatīt nodaļas 4. 4 un 5.